Novartis' Signature speeds up clinical trials
This article was originally published in Scrip
You may also be interested in...
Bristol's early development lead exec Mike Burgess explains how the company is embracing adaptive trial design to rapidly test combinations of immuno-oncology drugs old and new, plus targeted agents.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.